GlaxoSmithKline Plc has announced that it expects to take a 2010 fourth quarter charge of £2.2 billion relating to additional provisioning for a US investigation of its US sales practices and for product liability cases regarding Avandia (rosiglitazone).
Abbott Laboratories Ltd has decided to withdraw its European marketing authorisation application for Ozespa (briakinumab) which was intended to be used for moderate to severe chronic plaque psoriasis in adults, according to the EMA.
Merck Serono has entered into an exclusive development and licensing agreement with Domain Therapeutics SA of France to develop drugs that target a member of the GPCR family of proteins for neurodegenerative diseases.
Merck & Co has stopped a late-stage clinical trial of its anti-clotting drug, vorapaxar, and restricted a second study on the advice of an independent data and safety monitoring board. A regulatory filing for the drug had been planned in 2011.
Boehringer Ingelheim GmbH of Germany and Eli Lilly and Company have agreed to jointly develop and commercialise four of their diabetes assets in a deal that will bring several technologies under one roof.
GlaxoSmithKline Plc has agreed to pay $20 million upfront to Epizyme Inc of Cambridge, Massachusetts for access to technology that targets histone methyltransferases (HMT), a class of epigenetic enzymes. The goal is to develop small molecule drugs against cancer and other diseases.
The Netherlands-based diagnostics company, Qiagen NV, has acquired a minority stake in a German start-up company, Alacris Theranostics GmbH, which has a genome sequencing technology that can be used to generate biomarkers.
Neovacs SA of France is set to start a Phase 2 trial of its active immunotherapy in patients with Crohn’s disease. This follows an earlier study in Crohn’s that elicited an antibody response where nearly half the patients achieved disease remission.
DBV Technologies SA has secured $25.5 million in a Series C round to support clinical development of a skin patch to treat peanut allergies. The round was co-led by new investors InnoBio Fund and Lundbeckfond Ventures.
Dublin, Ireland-based Amarin Corporation Plc has raised a net $100.2 million in a secondary offering of its American Depositary Shares, the proceeds of which will be used to support the commercialisation of its lead cardiovascular product, AMR101.